Astrazeneca Ab

Bernard Barlaam

Johannes Wilhelmus Maria Nissink

James Stewart Scott

Bin Yang

Thomas Andrew Moss

Samantha Jayne Hughes

Kurt G Pike

Daniel Hillebrand O'Donovan

Christine Marie Paul Lambert-Van Der Brempt

Patrick Ple

Michelle Lamb

Alexander Hird

Melissa Vasbinder

Christopher De Savi

Remy Robert Morgentin

Andrew John Eatherton

Janet Hawkins

Thomas Anthony Hunt

Sebastien Louis Degorce

Jeffrey Gilbert Varnes

Dedong Wu

Frederick Woolf Goldberg

David Berry

Qibin Su

Benedicte Delouvrie

Gary Peter Tomkinson

Gary Patrick Reid

Craig Steven Harris

Sudhir Mahadeo Hande

Avipsa Ghosh

Gilles Ouvry

Michael Steven Bodnarchuk

Phillip Lichtor

Kun Song

James Sheppeck

Reem Telmesani

Dan Anders Broo

Helen Elizabeth Jones

Sebastien Louis Degeorge

Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, and Rare as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

2,6,9-trisubstituted purines

The specification generally relates to compounds of Formula (I): or a stereoisomer or pharmaceutically salt thereof, wherein G, G, G, X, Y, R, R, Q, Q, and Qhave any of the meanings defined herein, together with compositions containing them and their use in therapy. The compounds are inhibitors of the polymerase, DNA polymerase theta (Polθ or POLQ), and are thereby particularly useful in the treatment of cancer.

POLQ inhibitors

The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.

Chemical compounds

The specification generally relates to compounds of Formula (I): 

Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

Pyridine and pyrimidine derivatives

Selective estrogen receptor down-regulators

The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Growing community of inventors

Cambridge, United Kingdom

Bernard Barlaam